Sphere Fluidics Ltd.. (3/26/19). "Press Release: Sphere Fluidics Hires 10 New UK and US Staff in Its Plan to Scale Internationally". Cambridge.

	Region	United States (USA)
	Organisation	Sphere Fluidics Ltd.
	Group	Sphere Fluidics (Group)
	Organisation 2	Sphere Fluidics Inc.
	Group	Sphere Fluidics (Group)
	Product	Cyto-Mine® Single Cell Analysis System
	Product 2	microfluidics technology
	Person	Marchmont, Robert (Rob) (Sphere Fluidics 201903 VP Sales + Marketing before Protein Forest + GE Healthcare)
	Person 2	Campbell, Andrew (Sphere Fluidics 201903– Director of Finance before Charles River + PerkinElmer Life Sciences)

Rob Treanor joins as Director of Operations and Andrew Campbell as Director of Finance

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites. Rob Treanor and Andrew Campbell join Sphere Fluidics as Director of Operations and Director of Finance, respectively alongside new hires to its sales, operations and scientific teams. These appointments will expand the Company’s commercial capabilities and facilitate service and support for new and existing Cyto-Mine® customers in both the UK and US.

Rob Treanor joins Sphere Fluidics as Director of Operations and will be responsible for the manufacturing, supply chain and quality control. He will drive commercial operations and streamline processes to extend Sphere Fluidics’ product offering and deliver services to more customers. He has extensive experience running large logistics and supply teams within the biotechnology sector.

Sphere Fluidics has also appointed Andrew Campbell as its Director of Finance. Andrew has 20 plus years of financial management experience in financial planning, statutory reporting, cash management, tax and UK and US GAAP. He previously held senior positions at various global Life Sciences companies including, Charles Rivers and Perkin Elmer Life Sciences.

The Company has also made key appointments to its US Field Applications and Service Engineering teams to expand services and support for new and existing customers across North America. They will be supporting researchers in utilizing the Cyto-Mine Single Cell Analysis System to help customers identify and isolate rare cells of interest for biotherapeutic discovery and cell line development. Additionally, hires in marketing, product management and sales have been made.

Dr Rob Marchmont, VP of Sales and Marketing, Sphere Fluidics, said: “These hires follow Sphere Fluidics’ recent successful fundraising round and strong early market acceptance of our flagship Cyto-Mine instrument requiring us to expand and strengthen our commercial operations.”

Rob Treanor, Director of Operations, Sphere Fluidics, commented: “I am passionate about quality, efficiency and continuous improvement, and I’m excited to implement these qualities across operations at Sphere Fluidics, particularly at this pivotal and exciting stage of the Company’s growth.”

Andrew Campbell, Director of Finance, Sphere Fluidics, commented: “I look forward to growing Sphere Fluidics’ Finance team as we strive to deliver outstanding financial performance and growth at this critical moment of international expansion.”

For more information about Sphere Fluidics’ team, please visit:
https://spherefluidics.com/about-us/management-team

ENDS

Notes to Editors

Rob Treanor, Director of Operations, Sphere Fluidics
Andrew Campbell, Director of Finance, Sphere Fluidics

For high-resolution images please contact Zyme Communications.

For further information please contact:

Sphere Fluidics

Dr Rob Marchmont
Tel: +44 (0)1223 804200
Email: [email protected]

Zyme Communications

Dr Michelle Ricketts
Tel: +44 (0)7789 053885
Email: [email protected]

About Sphere Fluidics www.spherefluidics.com

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biotherapeutic discovery and cell line development.

Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented microfluidic picodroplet technology.

Sphere Fluidics is located in Babraham, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.

Record changed: 2023-06-05